Biotech Beast
Contributor since: 2015
Latest Articles
An Update On Corium International
Is It Time To Close Out The Omeros Corporation Trade?
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1)
Rhythm Pharmaceuticals Diversifies As A Major Catalyst Approaches
Rigel Pharmaceuticals To Test The FDA
Paratek: A Review Of Progress And Preview Of 2018
Zafgen's Pipeline Takes A Substantial De-Risking Step
Alexion Ups Its Game With ALXN1210 SC
Why Zafgen's Upcoming Catalyst Is So Important
Biotech Beast Positions For 2018: A Rising Tide Lifts Some Boats More Than Others
Why The Volatility In Omeros Corporation?
Acadia Pharmaceuticals: The Harmony Trial And Buyout Potential
Can Rhythm Pharmaceuticals Succeed Where Others Have Failed?
An In-Depth Look At Alexion's Competition And Upcoming Catalysts
Axsome Therapeutics Sweetens The Deal For Investors
A Balanced Take On Omeros
An Analysis Of Axsome Therapeutics' Upcoming Catalysts
A Deep Dive Into Minerva Neurosciences' Pipeline
Aimmune Therapeutics And DBV Technologies: Room For Both
Corium International Has A New Take On A Great Drug
Why Rigel Pharmaceuticals Investors Should Come Back Later
Is AEterna Zentaris Worth A Look?
Can Axovant Sciences Deliver In 2017?
Why You Should Own Rigel Pharmaceuticals, Inc.
Predicting The Outcome Of Alkermes' ALKS 5461 Phase III Program
Eli Lilly Can Save Transition Therapeutics Inc.
Caution With Cara Therapeutics This Quarter